These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15932835)

  • 21. Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.
    Stovall DW; Tanner-Kurtz K; Pinkerton JV
    Drugs; 2011 Sep; 71(13):1649-57. PubMed ID: 21902289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
    Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
    Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial.
    Pinkerton JV; Harvey JA; Pan K; Thompson JR; Ryan KA; Chines AA; Mirkin S
    Obstet Gynecol; 2013 May; 121(5):959-968. PubMed ID: 23635731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bazedoxifene: a selective estrogen-receptor modulator.
    Mitwally MF
    Womens Health (Lond); 2008 Jul; 4(4):319-26. PubMed ID: 19072496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.
    Christiansen C; Chesnut CH; Adachi JD; Brown JP; Fernandes CE; Kung AW; Palacios S; Levine AB; Chines AA; Constantine GD
    BMC Musculoskelet Disord; 2010 Jun; 11():130. PubMed ID: 20569451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA.
    Pinkerton JV; Bushmakin AG; Bobula J; Lavenberg J; Komm BS; Abraham L
    Menopause; 2017 Dec; 24(12):1372-1377. PubMed ID: 28609389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
    Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
    Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Investig Drugs; 2007 Oct; 16(10):1663-72. PubMed ID: 17922629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene.
    Fleischer AC; Wheeler JE; Yeh IT; Kravitz B; Jensen C; MacDonald B
    J Ultrasound Med; 1999 Jul; 18(7):503-12. PubMed ID: 10400054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women.
    Sturdee DW; Archer DF; Rakov V; Lang E;
    Climacteric; 2008 Feb; 11(1):63-73. PubMed ID: 18202966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis.
    Genant HK
    Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium.
    Goldstein SR; Scheele WH; Rajagopalan SK; Wilkie JL; Walsh BW; Parsons AK
    Obstet Gynecol; 2000 Jan; 95(1):95-103. PubMed ID: 10636510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.
    Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E
    Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.
    Taylor HS; Ohleth K
    Menopause; 2012 Apr; 19(4):479-85. PubMed ID: 22278343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
    Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S
    Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis.
    Kung AW; Chu EY; Xu L
    Expert Opin Pharmacother; 2009 Jun; 10(8):1377-85. PubMed ID: 19445558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
    Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
    Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.